Navamedic ASA: Growth and double-digit adjusted EBITDA margin in Q2 and first half 2026

Navamedic ASA: Change in leadership

Navamedic launches Virono®– the first single-dose over-the-counter cold sore tablet

Navamedic ASA: Minutes of Annual General Meeting

Navamedic ASA: Steady performance and continued product launch in Q1 2026

Navamedic ASA: Notice of Annual General Meeting